Delfi Diagnostics wraps up series B financing

2019 04 26 21 48 5250 Money Hundred Bills 400

Delfi Diagnostics announced Monday that it has raised $225 million in a series B financing round.

The funds will support continued development and commercialization of its liquid biopsy tests for single-cancer early detection, multicancer early detection, and treatment monitoring, according to the company.

Led by DFJ Growth, the financing round included participation from Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, and PTX Capital. All existing Delfi investors also participated, including Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, and Windham Venture Partners.

Page 1 of 4
Next Page